Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancer (Q37481198)
Jump to navigation
Jump to search
scientific article published on 25 October 2013
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancer |
scientific article published on 25 October 2013 |
Statements
1 reference
Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancer (English)
1 reference
Andres Forero-Torres
1 reference
Jeffrey R Infante
1 reference
David Waterhouse
1 reference
Lucas Wong
1 reference
Selwyn Vickers
1 reference
Edward Arrowsmith
1 reference
Aiwu Ruth He
1 reference
Lowell Hart
1 reference
David Trent
1 reference
James Wade
1 reference
Xiaoping Jin
1 reference
Qiang Wang
1 reference
Tashara Austin
1 reference
Michael Rosen
1 reference
Robert Beckman
1 reference
Reinhard von Roemeling
1 reference
Jonathan Greenberg
1 reference
Mansoor Saleh
1 reference
25 October 2013
1 reference
1 reference
925-932
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference
1 reference